68 results on '"Pohlman, Brad"'
Search Results
2. The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma
3. Validation of Pre-Treatment Modified Easix Score As a Predictor of Cytokine Release Syndrome Related to Anti CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia
5. Comparison of the Prognostic Value of Risk Assessment Tools in Allogeneic Hematopoietic Cell Transplantation
6. Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
7. Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel
8. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies
9. Toxicity Analysis of Busulfan Pharmacokinetic Guided Therapeutic Dose Monitoring for Myeloablative Conditioning Regimens with Allogeneic Transplantation
10. Advance Care Planning in Hematopoietic Stem Cell Transplant Recipients: A Survey of Providers in a Blood & Marrow Transplant Program
11. Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome in the Contemporary Era
12. The Impact of Clinical Pharmacists in Hematopoietic Stem Cell Transplant (HSCT) Outpatient Clinic at an Academic Medical Center
13. Measuring Patient-Reported Outcomes (PROs) in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients
14. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
15. Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma
16. Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma
17. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
18. Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting
19. Comparison of the Tolerability of Busulfan, Cyclophosphamide, Etoposide (BuCyVP) Versus Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) for Autologous Hematopoietic Cell Transplant (AHCT) in Hodgkin Lymphoma
20. Post-Transplant Radiation Had No Impact on Survival in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma
21. Evaluation of Corticosteroids for Engraftment Syndrome (ES) Prophylaxis in Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT) with High-Dose Melphalan (MEL)
22. Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome
23. Day 100 Risk Assessment Tool Predicts 1-Year Mortality after Allogeneic Hematopoietic Cell Transplantation
24. Pharmacokinetic-Guided Therapeutic Dose Monitoring (TDM) of Busulfan Reduces Relapse of Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplantation (ASCT)
25. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation
26. Low-Dose Lenalidomide after Non-Myeloablative Allogeneic Hematopoietic Cell Transplant with Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma
27. Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Umbilical Cord Blood Hematopoietic Cell Transplantation
28. Propensity Matched Analysis of Autologous Hematopoietic Stem Cell Transplantation Outcomes in Solid Organ Transplant Recipients
29. Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Haploidentical Hematopoietic Cell Transplantation Outcomes
30. Complication Rates and Resource Utilization in the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation (Allo HCT) Using Related Haploidentical Donors (Haplo) or Umbilical Cord Blood (UCB)
31. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience
32. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population
33. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
34. Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study
35. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome
36. Association of Socioeconomic Status (SES) with Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma
37. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times–Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
38. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
39. Evaluation of Ciprofloxacin in the Treatment of BK VIRUS-Associated Hemorrhagic Cystitis in Hematopoietic CELL Transplant Recipients
40. Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients with Non-Hodgkin's Lymphoma (NHL)
41. Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) after Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Older Patients with Myeloid Malignancies
42. Durable Long-Term Remission with Allogeneic Hematopoietic Cell Transplantation (HCT) for Relapsed/Refractory Follicular Lymphoma (FL)
43. Bortezomib-Based Induction Therapy PRIOR to High Dose Melphalan and Autologous Hematopoietic CELL Transplantation in Primary Amyloidosis
44. The Impact of Histologic Grade on Acute Graft Versus Host Disease Response and Outcomes
45. Single Nucleotide Gene Polymorphisms (SNP) in the Gamma Block of the Major Histocompatibility Complex (MHC) Are Independent Risk Factors for Severe Acute Graft Versus Host Disease (GVHD) in Unrelated Donor Hematopoietic Cell Transplantation (HCT)
46. Socioeconomic Status Influences Long-Term Outcomes in 1-Year Survivors after Allogeneic Hematopoietic Cell Transplantation
47. Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Cellular Infusion for Relapse after Transplant
48. Synergistic Effect of Major Histocompatibility Complex Class I–Related Chain A and Human Leukocyte Antigen–DPB1 Mismatches in Association with Acute Graft-versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation
49. Estimated radiation exposure and cancer risk from CT and PET/CT scans in patients with lymphoma
50. Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.